Abstract
In the treatment of patients with acute coronary syndrome in the pre-reperfusion era, one of the first-line drugs was beta-blockers. Now the management strategy of such patients has changed significantly. The results of these studies confirm the important role of beta-blockers in the therapy of patients who have undergone ACS in the era of reperfusion therapy. Beta-blocker therapy may be beneficial because of a potential reduction in the risk of all-cause death. The choice of vasodilatory drugs can provide benefits and additionally prevent the occurrence of complications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
